Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows in line with its trailing trend

Q1 FY2026 depreciation & amortization of $3.21M rose 2.1% year over year, ahead of the +0.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.4% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.

Context

  • Depreciation & amortization amounted to 4.2% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2.1% holds above the trailing-twelve-month pace of +0.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.21M+5.4% QoQ
Last fiscal yearDec 2025
$12.16M-3.7% YoY
LTMMar 2026
$12.61M+0.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.1%——
1 year-3.7%——
3-year CAGR-1.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
12.16M USD
Year-over-year change
-3.7%
4-year CAGR
+59.5%

Depreciation & Amortization vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.4% is the 8th highest of 9, against a peer median of +33.7%.
  • Depreciation & amortization amounts to 4.0% of revenue for XERS, versus a peer median of 1.5%.
XERS Competitors
Depreciation & Amortization for XERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€18.33M EUR+5.7%-1.8%1.5%
MNKDMannKind CorporationLTM Mar 2026$17.02M USD+70.2%+24.9%4.7%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$12.61M USD+0.4%-1.4%4.0%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$4.16M USD+116.2%+31.6%4.8%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$2.42M USD+28.0%-18.1%0.3%
SEPNSepterna, Inc.LTM Sep 2026$1.25M USD-21.5%—1.3%
GHRSGH Research PLCLTM Mar 2026$350K USD+12.5%+92.4%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$343K USD+39.4%+64.2%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$267K USD+621.6%-34.3%—
Peer median (excluding XERS) —+33.7%+24.9%1.5%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.